Not all that moves is tardive dyskinesia
- PMID: 1673323
- DOI: 10.1176/ajp.148.5.661
Not all that moves is tardive dyskinesia
Abstract
Objective: Because tardive dyskinesia and spontaneous dyskinesia appear the same, it is difficult to determine whether an individual patient's abnormal movements are induced by medication or have developed spontaneously. Therefore, estimates of the prevalence of tardive dyskinesia that are based on observations not adjusted for spontaneous dyskinesia are inflated. In addition, age is thought to be an important risk factor in the development of both tardive and spontaneous dyskinesias. The authors estimate the prevalence of both disorders for specific age groups.
Method: The authors reviewed nine reports on dyskinesia prevalence that included history of neuroleptic treatment and related prevalence to age. A rating of 2 or more on the Abnormal Involuntary Movement Scale or an equivalent score on another scale was considered an indication of dyskinesia. If the subject had taken neuroleptics for more than 3 months, the movement disorder was classified as neuroleptic-associated dyskinesia; other dyskinesias were considered spontaneous. The prevalence of tardive dyskinesia was defined as the rate of neuroleptic-associated dyskinesia minus the rate of spontaneous dyskinesia.
Results: The true rate of tardive dyskinesia was below 20% for all age groups except 70-79 years. The correlation between the rate of neuroleptic-associated dyskinesia and the rate of spontaneous dyskinesia was low.
Conclusions: After age 40 the prevalence of spontaneous dyskinesia is sufficiently high to conclude that many patients with diagnoses of tardive dyskinesia have abnormal movements attributable to causes other than neuroleptics.
Comment in
-
Prevalence of abnormal movement disorders associated with neuroleptics.Am J Psychiatry. 1992 Aug;149(8):1123-4. doi: 10.1176/ajp.149.8.aj14981123. Am J Psychiatry. 1992. PMID: 1353319 No abstract available.
-
Relation of age to prevalence of tardive dyskinesia.Am J Psychiatry. 1992 Jan;149(1):141. doi: 10.1176/ajp.149.1.141a. Am J Psychiatry. 1992. PMID: 1558561 No abstract available.
Similar articles
-
Prevalence of spontaneous dyskinesia in schizophrenia.J Clin Psychiatry. 2000;61 Suppl 4:10-4. J Clin Psychiatry. 2000. PMID: 10739325 Review.
-
Changing epidemiology of tardive dyskinesia: an overview.Am J Psychiatry. 1981 Mar;138(3):297-309. doi: 10.1176/ajp.138.3.297. Am J Psychiatry. 1981. PMID: 6110344 Review.
-
Clinical and epidemiologic aspects of tardive dyskinesia.J Clin Psychiatry. 1985 Apr;46(4 Pt 2):8-13. J Clin Psychiatry. 1985. PMID: 2858483
-
Spontaneous and tardive dyskinesias: clinical and laboratory studies.J Clin Psychiatry. 1985 Apr;46(4 Pt 2):42-7. J Clin Psychiatry. 1985. PMID: 2858480
-
Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.Am J Psychiatry. 1998 Apr;155(4):565-7. doi: 10.1176/ajp.155.4.565. Am J Psychiatry. 1998. PMID: 9546009
Cited by
-
Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.Curr Psychiatry Rep. 2011 Aug;13(4):295-304. doi: 10.1007/s11920-011-0202-6. Curr Psychiatry Rep. 2011. PMID: 21519907 Review.
-
Childhood pegboard task predicts adult-onset psychosis-spectrum disorder among a genetic high-risk sample.Schizophr Res. 2016 Dec;178(1-3):68-73. doi: 10.1016/j.schres.2016.08.017. Epub 2016 Sep 9. Schizophr Res. 2016. PMID: 27623359 Free PMC article.
-
Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.Psychopharmacology (Berl). 1996 Feb;123(4):307-14. doi: 10.1007/BF02246639. Psychopharmacology (Berl). 1996. PMID: 8867868
-
Prevalence of spontaneous dyskinesia in first episode, drug naive schizophrenia, and its relation to the positive and negative symptoms of schizophrenia.Open J Psychiatry Allied Sci. 2017 Jul-Dec;8(2):113-123. doi: 10.5958/2394-2061.2017.00005.2. Epub 2016 Dec 30. Open J Psychiatry Allied Sci. 2017. PMID: 31304241 Free PMC article.
-
Overcoming barriers to effective management of tardive dyskinesia.Neuropsychiatr Dis Treat. 2019 Apr 4;15:785-794. doi: 10.2147/NDT.S196541. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 31040678 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical